Glycoera using megaround for precision approach to immunology
With new $130M series B, the company is using an extracellular protein degrader to improve speed and depth of IgG4 removal.
With an approach to depleting autoantibodies that’s designed to be more precise than current treatments, Glycoera has drawn a $130 million series B round to take its extracellular protein degrader program into the clinic. Finding modalities to fully, durably and specifically deplete pathogenic autoantibodies has been challenging. Glycoera is going after IgG4-driven autoimmune diseases. The IgG4 subclass represents less than 5% of the IgG pool, yet current treatments deplete all the subclasses.
